Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for gemcitabine-induced thrombotic microangiopathy
2020-003168-22Phase 2Active
- Sponsor
- Rouen University Hospital
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in thrombotic microangiopathies (TMA), sponsored by Rouen University Hospital. Primary endpoint: Time to renal remission. Started Jun 2021; status: active.
02
Drugs
eculizumab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2020-003168-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003168-22.